National Institutes of Health: Granuloma trials

The registry lists 23 Granuloma studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 5 have results posted.

Early Phase 1 1Phase 1 12Phase 2 5Phase 3 1Phase 4 2No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and GranulocytesRecruitingNCT00001405
• Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant CyclophosphamideTerminatedNCT02282904Phase 1/2Results posted
• Comparing Xperguide vs. Conventional Methods During Percutaneous Image Guided ProceduresTerminatedNCT01287013Not applicableResults posted
• Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous DiseaseTerminatedNCT01147042Phase 4Results posted
• Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2Results posted
• Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous DiseaseTerminatedNCT00325078Phase 1/2Results posted
• Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995Status unknownNCT02082353
• Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous DiseaseWithdrawnNCT01851460Phase 1
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• Gene Therapy for Chronic Granulomatous DiseaseTerminatedNCT00394316Early Phase 1
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Use of Busulfan as Conditioning Agent for a Second Stem Cell TransplantCompletedNCT00092937Phase 1
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung CancerCompletedNCT00068497Not applicable
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck CancerCompletedNCT00023959Phase 1
• Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of CareCompletedNCT00023192Phase 3
• Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous DiseaseCompletedNCT00006417Phase 2
• Learning and Behavior Problems in Children With Chronic Granulomatous Disease and Related DisordersCompletedNCT00005933
• Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous DiseaseCompletedNCT00001765Phase 1
• Gene Therapy for Chronic Granulomatous Diseases - Long-term Follow-upCompletedNCT00001476Phase 1
• A Phase IV Study of Recombinant Human Gamma Interferon in Patients With Chronic Granulomatous Diseases of ChildhoodCompletedNCT00001317Phase 4